Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives $10.33 Consensus Target Price from Analysts

Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) have been assigned a consensus rating of “Buy” from the five research firms that are currently covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $10.33.

Several analysts recently commented on CRBU shares. Citigroup dropped their target price on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, November 26th. Bank of America dropped their price objective on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Caribou Biosciences in a research note on Wednesday, March 19th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CRBU. Public Employees Retirement System of Ohio purchased a new stake in Caribou Biosciences in the 4th quarter worth $222,000. Two Sigma Investments LP raised its position in shares of Caribou Biosciences by 23.7% during the 4th quarter. Two Sigma Investments LP now owns 1,118,696 shares of the company’s stock worth $1,779,000 after purchasing an additional 214,239 shares during the last quarter. Two Sigma Advisers LP lifted its stake in Caribou Biosciences by 39.5% in the 4th quarter. Two Sigma Advisers LP now owns 1,470,700 shares of the company’s stock valued at $2,338,000 after buying an additional 416,600 shares in the last quarter. Nuveen Asset Management LLC boosted its holdings in Caribou Biosciences by 23.6% in the 4th quarter. Nuveen Asset Management LLC now owns 330,831 shares of the company’s stock worth $526,000 after buying an additional 63,096 shares during the last quarter. Finally, Millennium Management LLC increased its stake in Caribou Biosciences by 52.9% during the 4th quarter. Millennium Management LLC now owns 859,825 shares of the company’s stock worth $1,367,000 after buying an additional 297,351 shares in the last quarter. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Stock Down 5.8 %

Caribou Biosciences stock opened at $0.96 on Friday. The stock has a 50-day moving average price of $1.27 and a 200 day moving average price of $1.72. The company has a market capitalization of $89.32 million, a price-to-earnings ratio of -0.58 and a beta of 2.34. Caribou Biosciences has a 52 week low of $0.92 and a 52 week high of $5.50.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings results on Monday, March 10th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.01. The company had revenue of $2.08 million for the quarter, compared to analyst estimates of $2.11 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. Research analysts anticipate that Caribou Biosciences will post -1.64 EPS for the current fiscal year.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.